When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PRNB - Principia Biopharma Inc.: Setting The Record Straight On BTK Inhibition
Principia Biopharma Inc.
In our original report on Principia Biopharma, we emphasized that BTK inhibitors have failed over and over in autoimmune diseases, which we attribute to a basic problem with their mechanism of action: their main effect is to impair the production of new B-cell lineages, leaving the previously established B-cell populations that cause autoimmunity largely unscathed. Alas, Sanofi – the French pharma firm that licensed Principia’s BTK inhibitor SAR442168 for use in multiple sclerosis – doesn’t seem to have gotten the memo. During Sanofi’s recent earnings call, its global head of R&D rattled off what